Serum and Aqueous Humor Levels of Fetuin-A in Pseudoexfoliation Syndrome

References

• Schlötzer-Schrehardt U, Naumann GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 2006;141:921–937.
   PubMed Web of Science ®Google Scholar
• Ritch R, Schlötzer-Schrehardt U. Exfoliation (pseudoexfoliation) syndrome: toward a new understanding. Proceedings of the First International Think Tank. Acta Ophthalmol Scand 2001;79:213–217.
   Google Scholar
• Wang W, He M, Zhou M, Zhang X. Ocular pseudoexfoliation syndrome and vascular disease: a systematic review and meta-analysis. PLoS One 2014;9:e92767.
   PubMed Web of Science ®Google Scholar
• Türkyilmaz K, Oner V, Ciçek Y, Kurt A, Durmuş M. Systemic arterial stiffness in patients with pseudoexfoliation glaucoma. J Glaucoma 2014;23:e108–11.
   PubMed Web of Science ®Google Scholar
• Alpaslan M, Karalezli A, Borazan M, Köktekir BE, Müderrisoğlu IH. Decreased aortic root elasticity-as a novel systemic manifestation of the pseudoexfoliation syndrome: an observational study. Anadolu Kardiyol Derg 2012;12:483–487.
   PubMedGoogle Scholar
• Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E et al. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 2007;66:246–250.
   PubMed Web of Science ®Google Scholar
• Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006;113:1760–1767.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827–833.
   PubMed Web of Science ®Google Scholar
• Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S et al. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism 2010;59:873–878.
   PubMed Web of Science ®Google Scholar
• Chylack LT Jr, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL et al. The lens opacities classification system III. The longitudinal study of cataract study group. Arch Ophthalmol 1993;111:831–836.
   Google Scholar
• Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383–2392.
   PubMed Web of Science ®Google Scholar
• Roos M, Richart T, Kouznetsova T, von Eynatten M, Lutz J, Heemann U et al. Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept 2009;154:39–43.
   PubMed Web of Science ®Google Scholar
• Wang H, Sama AE. Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med 2012;12:625–633.
   PubMed Web of Science ®Google Scholar
• Bucak YY, Tosun M, Simavli H, Onder HI, Erdurmuş M. Serum Levels of Omentin in Pseudoexfoliation Syndrome. J Glaucoma. 2014 Sep 26. [ Epub ahead of print]
   Google Scholar
• Türkyılmaz K, Öner V, Kırbas A, Sevim MS, Sekeryapan B, Özgür G et al. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. Eye (Lond) 2013;27:854–859.
   PubMed Web of Science ®Google Scholar
• Sorkhabi R, Ghorbanihaghjo A, Ahoor M, Nahaei M, Rashtchizadeh N. High-sensitivity C-reactive protein and tumor necrosis factor alpha in pseudoexfoliation syndrome. Oman Med J 2013;28:16–19.
   PubMedGoogle Scholar
• Altintas O, Yuksel N, Sonmez GT, Ozkan B, Altintas L, Caliskan Ş et al. Serum antiphospholipid antibody levels in pseudoexfoliation. J Glaucoma 2012;21:326–330.
   PubMed Web of Science ®Google Scholar
• Cumurcu T, Ozyurt H, Demir HD, Yardim H. Serum alpha-1-antitriypsin levels in patients with pseudoexfolative syndrome. Curr Eye Res 2008;33:159–162.
   PubMed Web of Science ®Google Scholar
• Sarenac Vulovic TS, Pavlovic SM, Zdravkovic NS. Proinflammatory cytokines induce XFG development. Ocul Immunol Inflamm 2015:1–7. [Epub ahead of print]
   Web of Science ®Google Scholar
• Yildirim Z, Yildirim F, Uçgun NI, Sepici-Dinçel A. The role of the cytokines in the pathogenesis of pseudoexfoliation syndrome. Int J Ophthalmol 2013;6:50–53.
   PubMed Web of Science ®Google Scholar
• Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 2011;6:e16945.
   PubMed Web of Science ®Google Scholar
• Küchle M, Nguyen NX, Hannappel E, Naumann GO. The blood-aqueous barrier in eyes with pseudoexfoliation syndrome. Ophthalmic Res 1995;1:136–142.
   Google Scholar
• Wang H, Li W, Zhu S, Li J, D’Amore J, Ward MF et al. Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats. J Cereb Blood Flow Metab 2010;30:493–504.
   PubMed Web of Science ®Google Scholar
• Helbig H, Schlötzer-Schrehardt U, Noske W, Kellner U, Foerster MH, Naumann GO. Anterior-chamber hypoxia and iris vasculopathy in pseudoexfoliation syndrome. Ger J Ophthalmol 1994;3:148–153.
   PubMedGoogle Scholar
• Schlötzer-Schrehardt U, Zenkel M, Küchle M, Sakai LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res 2001;73:765–780.
   PubMed Web of Science ®Google Scholar
• Wikner NE, Persichitte KA, Baskin JB, Nielsen LD, Clark RA. Transforming growth factor-beta stimulates the expression of fibronectin by human keratinocytes. J Invest Dermatol 1988;91:207–212.
   PubMed Web of Science ®Google Scholar
• Morales TI, Roberts AB. Transforming growth factor beta regulates the metabolism of proteoglycans in bovine cartilage organ cultures. J Biol Chem 1988;263:12828–12831.
   PubMed Web of Science ®Google Scholar
• Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001;45:265–315.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Koliakos GG, Karabatsas CH, Liakos P, Schlötzer-Schrehardt U, Georgiadis N et al. Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma. Exp Eye Res 2006;82:319–322.
   PubMed Web of Science ®Google Scholar
• Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755–12761.
   PubMed Web of Science ®Google Scholar
• Kottler UB, Jünemann AG, Aigner T, Zenkel M, Rummelt C, Schlötzer-Schrehardt U. Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon’s capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp Eye Res 2005;80:121–134.
   PubMed Web of Science ®Google Scholar
• Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye (Lond) 1994;8:188–195.
   PubMed Web of Science ®Google Scholar
• Schlötzer-Schrehardt U, Körtje KH, Erb C. Energy-filtering transmission electron microscopy (EFTEM) in the elemental analysis of pseudoexfoliative material. Curr Eye Res 2001;22:154–162.
   PubMed Web of Science ®Google Scholar